false 0001534525 0001534525 2024-10-29 2024-10-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________________

 

FORM 8-K

________________________

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 29, 2024

________________________

 

Xenetic Biosciences, Inc.

(Exact name of registrant as specified in charter)

 

Nevada   001-37937   45-2952962
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

945 Concord Street  
Framingham, Massachusetts 01701
(Address of principal executive offices) (Zip Code)

 

(781) 778-7720

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.001 par value per share   XBIO   The Nasdaq Stock Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

   

 

 

 

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On October 29, 2024, James E. Callaway and Adam Logal, each a member of the board of directors (the “Board”) of Xenetic Biosciences, Inc. (the “Company”), informed the Company of their intention to not stand for re-election at the Company’s 2024 Annual Meeting of Stockholders. Neither Dr. Callaway nor Mr. Logal’s decision was related to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. The Company thanks Dr. Callaway and Mr. Logal for their dedicated Board service.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 2 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  XENETIC BIOSCIENCES, INC.
   
  By: /s/ James Parslow                                        
Date: October 31, 2024 Name:   James Parslow
  Title:     Interim Chief Executive Officer & Chief Financial Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 3 
v3.24.3
Cover
Oct. 29, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 29, 2024
Entity File Number 001-37937
Entity Registrant Name Xenetic Biosciences, Inc.
Entity Central Index Key 0001534525
Entity Tax Identification Number 45-2952962
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 945 Concord Street
Entity Address, City or Town Framingham
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01701
City Area Code (781)
Local Phone Number 778-7720
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol XBIO
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Grafico Azioni Xenetic Biosciences (NASDAQ:XBIO)
Storico
Da Dic 2024 a Gen 2025 Clicca qui per i Grafici di Xenetic Biosciences
Grafico Azioni Xenetic Biosciences (NASDAQ:XBIO)
Storico
Da Gen 2024 a Gen 2025 Clicca qui per i Grafici di Xenetic Biosciences